Jubilant Life's stock soared 10.36 per cent to settle at Rs 159.85 on the BSE. In intra-day session, it advanced by 12.77 per cent to Rs 16...

The generic version of Novartis’ Diovan is used for treatment of hyper-tension. The current annualized US market size for the drugs is $2 b...

The drug firm has received final approval from the US health regulator for Valsartan tablets and plans to launch the product immediately.

The tablets are indicated for treatment of hypertension and are the generic versions of Novartis Pharmaceuticals Corporation's Diovan table...

Ranbaxy's net loss in the April-June quarter was at Rs 186 crore ($30.94 million), compared with a loss of Rs 524 crore a year earlier.

Ranbaxy Laboratories, which has been facing regulatory hurdles in the US, has been allowed to sell generic Valsartan tablets.

The stock has gained 25% in the last one year – and has been one of the best performing stocks among the frontline pharma companies.

Lupin today said it has received US health regulator's approval to market generic version of Novartis Pharmaceuticals Corp's Diovan HCT Tab...

In a statement, Aurobindo said the drug, a generic equivalent to Novartis Pharmaceuticals Corp's Diovan HCT Tablets, is ready for launch.

The Gurgaon-based firm has provisioned Rs 186 crore to deal with the costs arising out of the product recall.

Ranbaxy Laboratories has started shifting production of its generic version of the world's bestselling drug Lipitor from the US to its new ...